Droxidopa (Northera): A Hopeful Pill for Standing Dizziness in Neurogenic Orthostatic Hypotension

A man in his late sixties comes to clinic with his wife. He has Parkinson’s disease, and for the past year the dizziness on standing has shrunk his world. He can’t get up from the dinner table without gripping the chair. Twice he’s gone down in the hallway. We’ve already done the foundational work: we trimmed the blood pressure medicines he no longer needed, built up his water and salt, added compression stockings, and taught him to rise slowly and pump his calves first. He’s better. He wants to be steadier still. His standing blood pressure still dips and the room still grays. This is exactly the patient droxidopa was made for, and a few weeks later he’s walking his wife to the car without a hand on the wall.

That kind of turnaround is what makes this medicine worth understanding. Neurogenic orthostatic hypotension is a specific problem with a specific, treatable fix. The word “neurogenic” is the part that matters. It means the dizziness comes from a nervous system that can no longer tighten the blood vessels on cue, not from a water pill or a hot afternoon. When lifestyle measures and a cleaned-up medication list take you partway, droxidopa is one of the two pills that can carry you the rest of the way. This guide walks through what it is, who it helps, how we dose it, the one thing we keep an eye on, and why so many people are glad they tried it. For the broader picture of standing dizziness and its many causes, start with my guide to orthostatic hypotension.

What Droxidopa Is and Who It Helps

Droxidopa, brand name Northera, is a prescription pill approved for symptomatic neurogenic orthostatic hypotension in adults. It treats the dizziness, the lightheadedness, and that sinking about-to-black-out feeling on standing, in people whose autonomic nervous system has been worn down by a defined set of conditions.

The approval is focused on purpose, and that focus is good news for the people it fits. Droxidopa is for neurogenic orthostatic hypotension caused by primary autonomic failure, the umbrella term for three conditions: Parkinson’s disease, multiple system atrophy, and pure autonomic failure. It’s approved as well for a rare inherited enzyme deficiency called dopamine beta-hydroxylase deficiency, and for non-diabetic autonomic neuropathy, meaning nerve damage to the autonomic system that isn’t from diabetes.

What ties all of these together is a single broken reflex. In a healthy person, standing up triggers an instant tightening of the blood vessels in the legs and belly, which keeps blood from pooling and keeps pressure flowing up to the brain. In these conditions the nerves that fire that reflex are damaged, so the vessels stay loose, blood pools, and pressure falls. Droxidopa doesn’t repair the nerves. It supplies the chemical signal those nerves can no longer deliver, which is often enough to get you back on your feet with confidence.

If your standing dizziness comes from dehydration, blood loss, time spent in bed, or a medication like a water pill or a prostate drug, droxidopa isn’t the tool for the job, and that’s worth knowing too. Those causes have their own straightforward fixes, and the right first move is almost always a careful look at your medication list. Droxidopa earns its place when the cause is the nervous system itself, and there it can do real good.

How Droxidopa Works

Droxidopa is a building block your body turns into norepinephrine, the natural chemical your nerves normally release to tighten blood vessels. More norepinephrine means firmer vessels, and firmer vessels hold your blood pressure up when you stand. It supports your pressure without speeding up or slowing down your heart.

Norepinephrine is the body’s own pressure chemical. When the autonomic nerves are healthy, they release it right at the blood vessel walls to firm them up on demand. In neurogenic orthostatic hypotension, that local release runs short. Droxidopa works around the shortfall by handing the body a raw ingredient it can convert into norepinephrine using an enzyme that’s spread widely throughout the body rather than confined to the worn-down nerves. The result is more norepinephrine available to tighten the arteries and veins, which lifts your blood pressure right when you need it.

A few features make it well suited to this job. It raises pressure by firming both the arteries and the veins that return blood to the heart. It has no meaningful effect on heart rate, standing or lying down, which is reassuring in people who already have unsteady heart rate control. It reaches its peak in the bloodstream about two hours after you swallow it, so we time the doses across the day to match your active hours. Researchers checked carefully for any effect on the heart’s electrical timing at doses well above the usual range and found none, which adds to the comfort of using it.

Who Is a Good Candidate

The best candidate has confirmed neurogenic orthostatic hypotension, real symptoms that get in the way of daily life, and has already put the non-drug measures in place. Droxidopa is the helpful layer we add once that foundation is set, and it tends to shine in people who fit this picture.

Before I prescribe it, I like a few things settled, and getting them settled is part of what makes the medicine work well. First, the diagnosis. We confirm that your pressure truly drops on standing by measuring it lying down and then at one and three minutes after you rise. A tilt table test is sometimes added when the picture is subtle or the drop is delayed. Second, the cause. We make sure this is a neurogenic problem from Parkinson’s, multiple system atrophy, pure autonomic failure, or another autonomic condition.

Third, the foundation. By the time we talk about droxidopa, you’ve usually built some good habits already: drinking more water, taking in more salt if your other conditions allow, wearing compression garments, sleeping with the head of the bed up, and using counter-pressure tricks like crossing your legs or clenching your fists when symptoms hit. Droxidopa does its best work as the layer on top of those habits, and the two together often add up to more than either alone.

Here’s the honest, hopeful framing. About two-thirds of people who try droxidopa get a real lift in their standing blood pressure from it. For the smaller group who don’t, we have a clear next step ready, so nobody is left without a plan. I’ll come back to who tends to respond best, since it’s one of the more useful things to understand going in.

How It’s Dosed and Taken

Droxidopa starts low and rises gently. The usual starting dose is 100 mg three times a day, and we step it up in 100 mg increases based on how you feel, up to a ceiling of 600 mg three times a day. The single habit that matters most is taking the last dose of the day at least 3 hours before you lie down for the night.

The dose is guided by your symptoms, not by a lab number, which means you’re a real partner in finding the right level. We start at 100 mg taken three times during the day, then step the dose up every day or two while you’re still symptomatic and feeling fine on it. Most people land somewhere in the middle of the range and stay there. The maximum is 600 mg three times daily, and there’s no advantage to pushing past it.

That bedtime rule is the one habit worth saying plainly, since it’s the part people sometimes forget. Droxidopa lifts your blood pressure, and the lift peaks a couple of hours after the dose. Taking the last dose at least 3 hours before bed lets that effect settle before your head hits the pillow, so you get the standing benefit during the day and a calm, well-controlled overnight. Take it consistently with regard to food, meaning either always with meals or always without, so the effect stays steady and predictable.

If you miss a dose, take the next one at its normal time. Don’t double up, and skip the idea of a late-evening dose to make up for a missed afternoon one. Keeping doses out of the bedtime window is what keeps the medicine working for you instead of against you overnight.

Keeping Your Pressure Steady, Lying Down and Standing

The one thing we manage closely is supine hypertension, meaning blood pressure that runs high when you lie flat. The same medicine that holds your pressure up standing can push it up lying down, and a couple of simple habits keep that balanced. Raising the head of the bed and the early-evening dosing are part of the treatment, and they work well.

Here’s the balance that defines this condition, and the reassuring part is how manageable it is. The nervous system change that drops your pressure standing often does the reverse when you lie down, letting pressure climb. Add a pressure-supporting medicine on top, and the lying-down numbers can run high if we ignore them. We don’t ignore them. This is a known, routine part of care, and we have a clear playbook for it.

The practical answer is gentle and low-tech. Raise the head of your whole bed several inches with risers or a wedge, rather than stacking pillows under your head. That slight head-up tilt uses gravity to keep your overnight pressure in a comfortable range. We pair that with the bedtime dosing rule, and in some patients we check blood pressure both standing and lying down at home so we can see the full picture and dial things in. The goal is a comfortable middle: enough pressure to stand and move freely, and a calm, controlled night. When lying-down pressure is well managed, which it usually is with these habits, droxidopa is a steady, dependable part of your day. If it ever runs high despite the habits, we simply adjust the dose or the timing, and that keeps your heart and brain protected over the long run.

Side Effects and What to Watch For

The most common side effects are headache, some dizziness, and nausea. They’re usually mild and usually settle with a small adjustment to the dose or timing. A few rare reactions are worth knowing about so you can act fast if they ever come up, especially around dose changes or when a Parkinson’s medicine is stopped suddenly.

In the studies, the side effect people noticed most was headache, in roughly one in eight, followed by some dizziness and nausea in the single-digit percentages. None of these are surprising for a medicine that gently raises blood pressure, and most ease with a timing tweak or a small dose change. Plenty of people have no trouble with it at all.

A rarer reaction deserves a quick flag, the kind you tuck away just in case. After the drug came to market, there were occasional reports of a serious condition with high fever and confusion that resembles a reaction called neuroleptic malignant syndrome. It tended to appear when the droxidopa dose was changed or when a patient’s levodopa, a common Parkinson’s medicine, was reduced or stopped abruptly. New high fever, stiffness, or confusion is an emergency, and your team needs to know right away. We coordinate any changes to your Parkinson’s medicines carefully so this stays a rare footnote rather than a worry.

Two more points for the record. Droxidopa can stir up heart conditions you already have, including reduced blood flow to the heart muscle, abnormal rhythms, and heart failure, so your full cardiac history is part of the decision to start it, and reviewing it together is part of how we keep you safe. The pill also contains a yellow coloring agent called tartrazine, which can prompt an allergic-type reaction in a small number of people, a little more often in those who react to aspirin. Allergic reactions to the drug itself, such as swelling, hives, or breathing trouble, are reasons to seek care promptly.

Medicines and Substances to Review First

Droxidopa stacks with other things that raise blood pressure, and with a couple of older antidepressant-type drugs that can push pressure too high. A quick review of your full medication and supplement list before you start keeps everything smooth.

Anything that raises blood pressure adds to droxidopa’s effect. That includes other pressure-supporting prescriptions like midodrine, over-the-counter decongestants such as those with ephedrine, and the triptan medicines people take for migraines. Combining any of these isn’t off-limits, it just calls for a deliberate plan and a little monitoring, which we set up together.

Two categories call for a firmer line. Older antidepressants called non-selective MAO inhibitors, and an antibiotic called linezolid that works the same way, are best avoided with droxidopa, since the combination can drive pressure up sharply. The selective MAO-B inhibitors used in Parkinson’s, rasagiline and selegiline, were allowed in the studies and sit fine alongside it.

One Parkinson’s-specific detail is worth knowing. Carbidopa, bundled with levodopa in standard Parkinson’s therapy, can soften droxidopa’s effect by interfering with the enzyme that converts it to norepinephrine. In practice the studies didn’t find that people on carbidopa needed a meaningfully different dose, so this rarely changes the plan. It’s one of the small things your neurologist and I keep an eye on together so droxidopa keeps pulling its weight.

Does It Keep Working Over Time?

Droxidopa clearly improves standing blood pressure and symptoms, and many people feel that difference fast. The formal proof that it holds for many months is a bit softer on paper, which is why we keep checking in rather than assuming. The result is a plan tailored to you: we continue what’s clearly helping and adjust what isn’t.

The short-term evidence is solid and encouraging. Across several placebo-controlled studies, people with neurogenic orthostatic hypotension from Parkinson’s, multiple system atrophy, and pure autonomic failure had higher standing blood pressure and fewer symptoms, with less dizziness and more comfortable standing and walking. The improvement in how people felt tracked with the rise in standing pressure, which is just what you’d hope to see from a medicine that works this way.

The longer-term picture is where a gentle caveat lives, and it’s more about how the studies were designed than about the drug letting people down. One maintenance study followed patients for eight weeks and found the symptom benefit didn’t clear a strict statistical bar past the two-week mark, so the official label asks doctors to reassess periodically. A separate open-label study, where everyone knew they were taking the drug, pointed to sustained benefit on standing pressure and symptoms out to a full year. Read together, these tell a reassuring story: the medicine can keep helping for a long time, and the help varies enough person to person that checking in is the smart, caring thing to do.

What this means for you is simple and reassuring. We start it, we watch whether your standing comfort and your numbers improve, and we keep checking at your visits. When it’s clearly helping, we stay the course. If the benefit ever fades, we revisit the plan together instead of leaving you on a pill that’s no longer doing its job.

Droxidopa Versus Midodrine

Droxidopa and midodrine are the two first-line pills for neurogenic orthostatic hypotension, and having two good options is a genuine advantage. No head-to-head trial has pitted them directly against each other. Midodrine appears a little more likely to raise lying-down pressure, while droxidopa tends to be well tolerated and is often the comfortable pick when lying-down pressure is already on our radar.

Patients ask which one is better, and the honest answer is that the right choice is the one that fits you, since we don’t have a clean trial ranking them. Both are first-line, and both raise standing pressure by firming up blood vessels through different mechanisms, so if one isn’t your match, the other often is.

The differences that guide the choice come from how each one behaves. A review of the evidence found midodrine more likely to push up lying-down pressure, the very thing we work to keep comfortable. Droxidopa tends to be well tolerated, and it doesn’t carry midodrine’s tendency toward urinary retention, a welcome point for older men with prostate issues. For a patient whose lying-down pressure already runs high, droxidopa is often the smoother fit. Some people do best on one, some on the other, and a few thrive on a carefully managed combination. The point is that we have room to find what works for you.

Why It Works Beautifully for Some

About two-thirds of people who try droxidopa get a real rise in standing blood pressure, and how well you respond seems to depend on the kind of autonomic wiring you have. People whose nerve change sits in the peripheral nerves, as in Parkinson’s disease and pure autonomic failure, tend to respond especially well. That’s useful to know going in, so we can set hopeful, honest expectations.

This is one of the more satisfying things to understand before starting. The drug supplies a norepinephrine building block, and the body still does the final step at the blood vessel, so the response depends on the wiring being primed in a particular way.

Researchers have found that the strongest responders tend to be people with change in the peripheral sympathetic nerves, the ones out near the blood vessels, who also have low resting norepinephrine when lying down. Their vessels have grown extra sensitive to the chemical, a phenomenon called denervation supersensitivity, so when droxidopa supplies the raw material, the vessels respond strongly and pressure comes up nicely. Parkinson’s disease and pure autonomic failure often fit this pattern. Multiple system atrophy, where the change sits higher up in the central nervous system, responds less predictably. None of this is a guarantee in either direction, which is why we treat the first few weeks as a friendly, real-world trial and let your actual response be the verdict.

Where It Fits in the Bigger Plan

Droxidopa is a helpful layer on a strong foundation. The base of treatment for neurogenic orthostatic hypotension is always the non-drug measures and a clean medication list. Droxidopa goes on top when those aren’t quite enough, and major guidelines support using it for exactly this purpose.

Every patient I treat for this starts with the same foundation, and it does a lot of good on its own. We review every medication and stop or shrink anything that drops pressure. We build up fluids and salt to the degree your heart and kidneys allow. We add compression, head-up sleeping, slow position changes, and counter-pressure maneuvers. For many people that gets them through the day comfortably. When it falls a little short, a pill like droxidopa or midodrine joins the team, layered on top of the habits rather than replacing them.

The professional guidance backs this up. The major syncope guideline from the American heart and cardiology societies gives droxidopa a solid, evidence-supported recommendation for people with fainting from neurogenic orthostatic hypotension. That same guidance notes the carbidopa interaction in Parkinson’s patients, the small detail we already keep an eye on. The basics remain the backbone of care, and droxidopa makes them go further.

When to Talk to Your Doctor

If you have Parkinson’s disease, multiple system atrophy, pure autonomic failure, or another autonomic condition, and standing dizziness is still limiting your life after the fluids, salt, compression, and medication changes, droxidopa is a hopeful conversation worth having. The same is true if you’re already on it and want to talk through how well it’s helping, or confirm your lying-down pressure is being managed comfortably.

If you have questions about neurogenic orthostatic hypotension or want help thinking through whether droxidopa fits your situation, our office is glad to help. To get in touch, visit our practice website. For coordinated cardiac and neurological care, we work with the team at San Diego Cardiovascular Associates. For the wider picture of standing dizziness and its causes, see my guides to orthostatic hypotension and lightheadedness versus passing out.

Common Questions Patients Ask Me

Is droxidopa the same as a blood pressure medicine?

It works in the opposite direction from the pills most people picture. Standard blood pressure medicines lower pressure. Droxidopa raises it, to keep it from falling when you stand. That’s why it’s reserved for people whose problem is low standing pressure from a nerve condition, and for them it’s a welcome fix.

How quickly will I know if it’s helping?

Often within the first week or two, since the effect on standing pressure shows up fast. We adjust the dose over days based on how you feel, so you’ll usually have an early sense that your standing comfort is improving. If your symptoms and numbers haven’t budged after a fair trial, we simply move to the next option, and there’s a good one ready.

Why do I take the last dose so early in the evening?

The medicine raises pressure, and the lift peaks a couple of hours after a dose. Taking the last dose at least 3 hours before bed lets that lift settle before you lie down, so you get the standing benefit by day and a calm, well-controlled night. It’s a small habit that makes the whole plan run smoothly.

Do I really need to raise the head of my bed?

Yes, and it’s an easy win. Raising the whole head of the bed several inches uses gravity to keep your overnight pressure comfortable. Stacking pillows under your head doesn’t do the same thing and can strain your neck. The bed angle and the early-evening dose are the two simple habits that keep droxidopa working safely.

Can I take it with my Parkinson’s medicines?

Usually yes, and many patients do. The selective Parkinson’s drugs rasagiline and selegiline sit fine alongside it. One ingredient in standard Parkinson’s therapy, carbidopa, can soften droxidopa’s effect a little, and that rarely changes the plan. We coordinate carefully whenever your Parkinson’s medicines change, so your neurologist and I are always working from the same page.

What if it isn’t my match?

It happens for a minority of people, and it’s not a dead end. If droxidopa doesn’t raise your standing pressure or ease your symptoms after a fair trial, we don’t keep you on it. Midodrine is the other first-line pill and works through a different mechanism, so it’s a natural next step. Fludrocortisone and other measures are on the menu too. Not responding to one drug doesn’t mean this condition can’t be managed well, because it usually can.

References

1. Northera (droxidopa) Prescribing Information. Lundbeck. U.S. Food and Drug Administration. Updated July 1, 2019.

2. Kaufmann, Horacio, Lucy Norcliffe-Kaufmann, Jose-Alberto Palma, et al. “Droxidopa for Neurogenic Orthostatic Hypotension: A Randomized, Placebo-Controlled, Phase 3 Trial.” Neurology 83, no. 4 (2014): 328-335.

3. Biaggioni, Italo, Horacio Kaufmann, et al. “Randomized Withdrawal Study of Patients with Symptomatic Neurogenic Orthostatic Hypotension Responsive to Droxidopa.” Hypertension 65, no. 1 (2015): 101-107.

4. Hauser, Robert A., L. Arthur Hewitt, Stuart Isaacson. “Droxidopa in Patients with Neurogenic Orthostatic Hypotension Associated with Parkinson’s Disease.” Journal of Parkinson’s Disease 4, no. 1 (2014): 57-65.

5. Shen, Win-Kuang, Robert S. Sheldon, David G. Benditt, et al. “2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients with Syncope.” Journal of the American College of Cardiology 70, no. 5 (2017): e39-e110.

6. Freeman, Roy, Ahmad R. Abuzinadah, Christopher Gibbons, et al. “Orthostatic Hypotension: JACC State-of-the-Art Review.” Journal of the American College of Cardiology 72, no. 11 (2018): 1294-1309.

7. Kaufmann, Horacio, Jose-Alberto Palma. “Droxidopa for Neurogenic Orthostatic Hypotension: Predictors of Response.” Autonomic Neuroscience: Basic and Clinical 211 (2018): 1-6.

8. Wieling, Wouter, Horacio Kaufmann, Victoria E. Claydon, et al. “Diagnosis and Treatment of Orthostatic Hypotension.” The Lancet Neurology 21, no. 8 (2022): 735-746.

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.